Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03797521 · ClinicalTrials.gov registry record · Phase 2
A Study in Patients With Trichotillomania
A Phase 2 study of Trichotillomania, sponsored by Promentis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 128
- Enrollment target
- 13
- Study locations
NCT03797521: Completed Phase 2 study of Trichotillomania, sponsored by Promentis Pharmaceuticals.
NCT03797521 is a Phase 2 study of Trichotillomania that has completed, run by Promentis Pharmaceuticals. The registered enrollment target is 128 participants, above the 56-participant average among 8 other Trichotillomania trials with a reported enrollment target (129% higher). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03797521, a Phase 2 study of Trichotillomania, has completed, sponsored by Promentis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 128 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 when dosed for 6 weeks versus placebo in adult patients with moderate to severe Trichotillomania.
Primary Outcome
Safety and tolerability assessed using the frequency of subjects with serious adverse events, adverse events leading to discontinuation, and adverse events judged to be related to study medication.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SXC-2023
Study Locations (13)
California
- CNRI- Los Angeles - Pico Rivera
- Artemis Institute for Clinical Research - Riverside
New York
- Integrative Clinical Trials, LLC - Brooklyn
- Finger Lakes Clinical Research - Rochester
Florida
- Behavioral Clinical Research - North Miami
Georgia
- iResearch Atlanta - Decatur
Illinois
- Univ of Chicago - Chicago
Louisiana
- Lake Charles Clinical Trials - Lake Charles
Massachusetts
- Massachusetts General Hospital - Boston
Ohio
- Insight Clinical Trials, LLC - Shaker Heights
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2018-12-19 |
| Est. Completion | 2019-12-16 |
| Phase | Phase 2 |
What the finished NCT03797521 record still lists
NCT03797521 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, above the 56-participant average among 8 other Trichotillomania trials with a reported enrollment target (129% higher).
The record links to 1 condition, with Trichotillomania appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03797521 lists 13 locations in 11 states (California, New York, Florida).
Frequently Asked Questions
What is clinical trial NCT03797521 about?
NCT03797521 is a clinical study titled "A Study in Patients With Trichotillomania". The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 when dosed for 6 weeks versus placebo in adult patients with moderate to severe Trichotillomania.
What is the current status of trial NCT03797521?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2018-12-19. Estimated completion is 2019-12-16.
What conditions does trial NCT03797521 study?
This clinical trial studies the following conditions: Trichotillomania.
What interventions are being tested in trial NCT03797521?
The interventions under investigation include: Placebo (DRUG), SXC-2023 (DRUG).
Who is sponsoring clinical trial NCT03797521?
This trial is sponsored by Promentis Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03797521 being conducted?
This trial has 13 study locations across California, Florida, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trichotillomania
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03797521's enrollment target sits among peer trials
128 2nd of 8 the highest of 8 other Trichotillomania trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Trichotillomania trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
N-Acetylcysteine for Pediatric Trichotillomania
COMPLETED · Phase 2
-
Technology Assisted Treatment of Trichotillomania: Open Trial
RECRUITING · NA
-
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
ACTIVE NOT RECRUITING · NA
-
Cognitive Behavioral Treatment of Pediatric Trichotillomania
COMPLETED · NA
-
Response Inhibition Training for Individuals With Trichotillomania
COMPLETED · NA
-
Cognitive Behavioral Therapy for Trichotillomania
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI